Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy set to benefit from Large Hadron Collider spin-off

Dr Michael Sinclair, CEO of Advanced Oncotherapy (LON:AVO), tells Proactive Investors his firm is uniquely placed to exploit a strand of particle physics from the Cern Laboratories to combat cancer tumours. Mike says that AVO is working towards producing proton beam therapy machines, at a fraction of the cost of existing machines, using its own patented technology.
Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use